ANV-419 Drug Asset Due Diligence Report 2026

This ANV-419 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether ANV-419 can convert its Fusion protein profile and IL-2R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	ANV-419 (query alias: ANV-419)
Modality / target	Fusion protein; IL-2R; IL-2R agonists
Highest global status	Phase 2
Originator	Anaveon AG
Active developers	Anaveon AG, Vall d'Hebron Institut d'Oncologia

The MCP disease footprint includes Non-Small Cell Lung Cancer, Unresectable Melanoma, Uterine Cervical Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06630611	Phase 2	Recruiting	40	Primary endpoint not disclosed in English source
NCT05641324	Phase 1	Terminated	4	Primary endpoint not disclosed in English source
NCT05578872	Phase 1/2	Completed	29	Primary endpoint not disclosed in English source

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A Phase 1/2 Study of ANV419 as Monotherapy or in Combination With Anti-PD-1 or Anti-CTLA-4 Antibody Following Anti-PD-1/Anti-PD-L1 Antibody Treatment in Patients With Unresectable or Metastatic Cutaneous Melanoma (OMNIA-1)

Phase 1/2; n=29; evaluation: Not stated in English source. Reported fields: Monotherapy Dose Expansion: Objective Response Rate (ORR) as Defined by RECIST v1.1 = 0 Pts ; Monotherapy Dose Expansion: Objective Response Rate (ORR) as Defined by RECIST v1.1 = 0 Pts

Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors

Phase 1; n=not disclosed; evaluation: Positive. Reported fields: MTD = 243 µg/kg

ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, induces selective effector cell proliferation in patients with progressed cancer

Phase 1/2; n=26; evaluation: Positive. Reported fields: -; AE(discontinuation) = 0 Pts

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

ANV-419 addresses Non-Small Cell Lung Cancer, Unresectable Melanoma, Uterine Cervical Cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Fusion protein—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The MCP screen returned 69 matched transaction record(s) under the scope “target-level comparable: IL-2R.” Partner activity is a market-validation signal, but it does not establish net present value.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: IL-2R records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-07-29	MPC to distribute ImmunityBio's ANKTIVA against NMIBC and NSCLC in the UAE	Approved	Financial terms not disclosed
2026-07-27	argenx Completes Acquisition of Forte Biosciences, Inc.	Phase 2	US$2,200.0M stated total
2026-02-19	ImmunityBio Expands Access to ANKTIVA® in EU with New Distribution Partnership and Opens Irish Subsidiary to Support European Launch	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Combined composition of modified cytokine and CD40 agonist and Anti-tumor use thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.

7. Principal risks and diligence gates

Clinical differentiation versus current standards and pipeline competitors
Safety, dose optimization, and long-term tolerability
Patent scope, territorial rights, manufacturing, and commercial positioning

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO